Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03522129 · ClinicalTrials.gov registry record · Phase 1
Study to Evaluate the Effect of CT1812 Treatment on Amyloid Beta Oligomer Displacement Into CSF in Subjects With Mild to Moderate Alzheimer's Disease
A Phase 1 study, sponsored by Cognition Therapeutics.
- Completed
- Registry status
- Phase 1
- Development phase
- 3
- Enrollment target
NCT03522129: Completed Phase 1 study, sponsored by Cognition Therapeutics.
NCT03522129 is a Phase 1 study that has completed, run by Cognition Therapeutics. The registered enrollment target is 3 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (95% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03522129, a Phase 1 study, has completed, sponsored by Cognition Therapeutics.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 3 participants
- Enrollment target
Study Summary
This is a multi-center, Phase 1b, randomized, double-blind, placebo-controlled parallel-group trial in adults with mild to moderate AD.
Primary Outcome
evidence of oligomer displacement as demonstrated by a clear rise in CSF oligomer concentration relative to baseline and placebo
Interventions
- DRUG Placebo
- DRUG CT1812
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3 participants |
| Start Date | 2018-05-30 |
| Est. Completion | 2019-02-06 |
| Phase | Phase 1 |
What the finished NCT03522129 record still lists
NCT03522129 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 3 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (95% lower).
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT03522129 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03522129 about?
NCT03522129 is a clinical study titled "Study to Evaluate the Effect of CT1812 Treatment on Amyloid Beta Oligomer Displacement Into CSF in Subjects With Mild to Moderate Alzheimer's Disease". This is a multi-center, Phase 1b, randomized, double-blind, placebo-controlled parallel-group trial in adults with mild to moderate AD.
What is the current status of trial NCT03522129?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 3 participants. The study started on 2018-05-30. Estimated completion is 2019-02-06.
What interventions are being tested in trial NCT03522129?
The interventions under investigation include: Placebo (DRUG), CT1812 (DRUG).
Who is sponsoring clinical trial NCT03522129?
This trial is sponsored by Cognition Therapeutics, which has 9 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03522129's enrollment target sits among peer trials
3 1999th of 2000 higher than 1 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI